Clazosentan 15 mg/h

DRUG2 trials

Sponsors

Idorsia Pharmaceuticals Ltd.

Conditions

Aneurysmal Subarachnoid Hemorrhage

Phase 2

Clazosentan in Preventing the Occurrence of Cerebral Vasospasm Following an Aneurysmal Subarachnoid Hemorrhage (aSAH)

CompletedNCT00111085

Idorsia Pharmaceuticals Ltd.Aneurysmal Subarachnoid Hemorrhage

Start: 2005-01-10End: 2006-03-30Updated: 2018-07-10

Phase 3

Clazosentan in Aneurysmal Subarachnoid Hemorrhage

TerminatedNCT00940095

Idorsia Pharmaceuticals Ltd.Aneurysmal Subarachnoid Hemorrhage

Start: 2009-07-01End: 2011-01-01Updated: 2018-07-09

Related Papers

Thick and Diffuse Subarachnoid Blood as a Treatment Effect Modifier of Clazosentan After Subarachnoid Hemorrhage

Stroke2019-08-0920 citations

Acute kidney injury after aneurysmal subarachnoid hemorrhage and its effect on patient outcome: an exploratory analysis

Journal of neurosurgery2019-07-1325 citations

Anemia After Aneurysmal Subarachnoid Hemorrhage Is Associated With Poor Outcome and Death

Stroke2018-06-2668 citations

Dissociation of Early and Delayed Cerebral Infarction After Aneurysmal Subarachnoid Hemorrhage

Stroke2016-11-0961 citations

The network topology of aneurysmal subarachnoid haemorrhage

Journal of Neurology Neurosurgery & Psychiatry2014-10-037 citations

Patient Phenotypes Associated With Outcomes After Aneurysmal Subarachnoid Hemorrhage

Stroke2014-01-1525 citations

Clinical, laboratory, and radiographic predictors of the occurrence of seizures following aneurysmal subarachnoid hemorrhage.

2013-04-1223 citations

Electrocardiographic changes predict angiographic vasospasm after aneurysmal subarachnoid hemorrhage.

2012-06-0733 citations

Attributing hypodensities on CT to angiographic vasospasm is not sensitive and unreliable.

2011-10-1320 citations